{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:32:34Z","timestamp":1785760354592,"version":"3.56.0"},"reference-count":45,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuromuscular Diseases"],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Data on the clinical course of Duchenne muscular dystrophy (DMD) exist from well-characterized clinical cohorts but estimates from real-world populations are fewer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The objective was to estimate the prevalence of key clinical milestones by age, among real-world commercially-insured DMD patients in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>MarketScan claims (2013\u20132018) were used to identify males with DMD. The percentages with wheelchair use or experiencing scoliosis, neurologic\/neuropsychiatric involvement, cardiomyopathy, and respiratory involvement were tabulated; as were the median (interquartile range [IQR]) ages at first observed occurrence within the claims data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among DMD patients ( n\u200a=\u200a1,964), the median (IQR) baseline age was 15 (9\u201321) years, and median follow-up was 1.7 years. Wheelchair use was observed in 55% of those aged 8 to 13 years at cohort entry; scoliosis, among 38% of those 8 to 10 and 52% of those 11 to 13 years; neurologic\/neuropsychiatric involvement, among 41\u201343% of those 8 to 13 years; respiratory involvement, among 45% of those 14 to 19 years; and cardiomyopathy, among 68% of those 14 to 16 and 58% of those 17 to 19 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The prevalence of key clinical milestones across ages was broadly consistent with published findings. Variability in estimates reflect clinical heterogeneity; these contemporary estimates from real-world data help characterize clinical outcomes in DMD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3233\/jnd-220816","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T11:06:22Z","timestamp":1665486382000},"page":"689-699","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Characterizing the Occurrence of Key Clinical Milestones in Duchenne Muscular Dystrophy in the United States Using Real-World Data"],"prefix":"10.1177","volume":"9","author":[{"given":"Shelagh M.","family":"Szabo","sequence":"first","affiliation":[{"name":"Broadstreet Health Economics & Outcomes Research, Vancouver BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa C.","family":"Klimchak","sequence":"additional","affiliation":[{"name":"Sarepta Therapeutics, Inc, Cambridge MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Qian","sequence":"additional","affiliation":[{"name":"Broadstreet Health Economics & Outcomes Research, Vancouver BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Iannaccone","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern, Harry Hines Blvd, Dallas TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Popoff","sequence":"additional","affiliation":[{"name":"Broadstreet Health Economics & Outcomes Research, Vancouver BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine L.","family":"Gooch","sequence":"additional","affiliation":[{"name":"Sarepta Therapeutics, Inc, Cambridge MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,10,8]]},"reference":[{"key":"ref001","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcl.2015.03.008"},{"key":"ref002","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01430-8"},{"key":"ref003","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23807"},{"key":"ref004","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(87)90579-4"},{"key":"ref005","doi-asserted-by":"publisher","DOI":"10.1111\/jpc.12868"},{"key":"ref006","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2014.07.006"},{"key":"ref007","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2014.02.006"},{"key":"ref008","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2013.04.005"},{"key":"ref009","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23807"},{"key":"ref010","unstructured":"Parent Project Muscular Dystrophy\nThe Duchenne Registry [Available from: 2019 https:\/\/www.duchenneregistry.org\/."},{"key":"ref011","unstructured":"Centers for Disease Control and Prevention\nMuscular Dystrophy Research and Tracking, 2019 [Available from: https:\/\/www.cdc.gov\/ncbddd\/musculardystrophy\/researchhtml."},{"key":"ref012","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001950"},{"key":"ref013","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.05.019"},{"key":"ref014","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002891"},{"key":"ref015","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2018.07.004"},{"key":"ref016","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01862-w"},{"key":"ref017","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-020-00613-8"},{"key":"ref018","doi-asserted-by":"publisher","DOI":"10.1177\/0883073816687422"},{"key":"ref019","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2013.05.060"},{"key":"ref020","unstructured":"Pharmacoepidemiology StromBL, KimmelSE, HennessyS, editors New York, NY: Wiley-Blackwell; 2019."},{"key":"ref021","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2017.23.6.633"},{"key":"ref022","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.27.10.1426"},{"key":"ref023","unstructured":"IBM Watson Health\nCOMMERCIAL CLAIMS AND ENCOUNTERS DATABASE AND MEDICARE SUPPLEMENTAL AND COORDINATION OF BENEFITS DATABASE, IBM Watson Health; 2017."},{"key":"ref024","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-017-1385-0"},{"key":"ref025","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000000115"},{"key":"ref026","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026391"},{"key":"ref027","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000000286"},{"key":"ref028","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2013.12.016"},{"issue":"8","key":"ref029","first-page":"494","volume":"6","author":"Broulette J","year":"2013","journal-title":"American Health & Drug Benefits"},{"key":"ref030","first-page":"ciw356","author":"Lykins J","year":"2016","journal-title":"Clinical Infectious Diseases"},{"key":"ref031","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2010.12.021"},{"key":"ref032","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.02.978"},{"key":"ref033","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"ref034","doi-asserted-by":"publisher","DOI":"10.1177\/0883073814558120"},{"key":"ref035","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000260974.41514.83"},{"key":"ref036","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2018.01.290"},{"key":"ref037","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26129"},{"key":"ref038","unstructured":"38 !!! INVALID CITATION !!! 16."},{"key":"ref039","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32160-8"},{"key":"ref040","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2017.12.004"},{"key":"ref041","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.12922"},{"key":"ref042","doi-asserted-by":"publisher","DOI":"10.3233\/JND-170280"},{"key":"ref043","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-020-02411-3"},{"key":"ref044","unstructured":"GoochKL, SzaboSM, AudhyaI, SalhanyR, QianC, KlimchakAC, editors. The feasibility of using US claims data to assess outcomes in Duchenne muscular dystrophy. AMCP; 2020."},{"key":"ref045","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1304-8"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JND-220816","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JND-220816","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JND-220816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:50:02Z","timestamp":1777506602000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JND-220816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,9,1]]}},"alternative-id":["10.3233\/JND-220816"],"URL":"https:\/\/doi.org\/10.3233\/jnd-220816","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]}}}